SAKK4106_1 | R Documentation |
Kaplan-Meier digitized data from SAKK4106, figure 1 (PMID 25605741). A reported sample size of 262 for a primary endpoint of TTP in colorectal cancer.
SAKK4106_1
A data frame of 262 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (bev, no_bev) | |
Koeberle D, Betticher DC, von Moos R, et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015; 26: 709–14.
summary(SAKK4106_1)
kmplot(SAKK4106_1)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.